APC Nutrapro Plasma
Nutrapro plasma (min. 78% crude protein) is one of the most research proven, most widely used and most beneficial components added to calf milk replacers in the USA.
There is a plethora of high-quality milk-fed calf research documenting the benefits associated with feeding spray-dried plasma proteins primarily incorporated in milk replacers but also supplemented via add packs to whole milk. There are 17 peer-reviewed calf trials that are published in respected journals comparing the addition of plasma at inclusion rates varying from 3% – 20% to all-milk formulas. There are also 20 ADSA/ASAS/JAM scientific abstracts examining plasma in milk replacers fed to calves. Many benefits to the calf are well documented. There are also published trials examining the effect of plasma when supplemented during an E coli, cryptosporidial enteritis, and coronavirus disease challenge (details available upon request). The addition of plasma is one of the most researched and field-proven (U.S. market share conservatively estimated at 35%) adjuncts incorporated in milk replacers. Detailed analysis of all trials is available upon request (Dave Wood, Animix, email@example.com).”
Published disease-challenge milk-fed calf papers worthy of review:
- Hunt E, Qiang F, Armstrong M, Rennix D, Webster D, Galanko J, Chen W,
Weaver E, Argenzio R, Rhoads M. Oral bovine serum concentrate improves
cryptosporidial enteritis in calves. Pediatric Res 2002; 51:370-376.
- Nollet H, Laevens H, Deprez P, Sanchez R, Van Driessche E, Muylle E. The
use of non-immune plasma powder in the prophylaxis of neonatal Escherichia
coli diarrhea in calves. Am J Vet Med 1999; 46:185-196.
- Quigley JD, Drew MD. Effects of oral antibiotics or bovine plasma on
survival, health, and growth in dairy calves challenged with Escherichia coli.
Food Ag Immunol 2000; 12:311-318.
- Arthington JD, Jaynes CA, Tyler HD, Kapil S, Quigley JD. The use of bovine
serum protein as an oral support therapy following coronavirus challenge
in calves. J Dairy Sci 2002; 85:1249-1254.